Jacob Van Naarden, Loxo COO (Loxo)
#ASH20 Loxo and Eli Lilly show off PhI/II data for their BTK inhibitor in two blood cancers
ASH is back and Loxo is primed and ready to present new data that they think will be quite exciting.
The Lilly-owned company is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
